TIGIT is a key inhibitory checkpoint receptor in lymphoma.

James K GodfreyXiufen ChenNicole SunseriAlan CooperJovian YuArina VarlamovaDmitry ZarubinYuriy PopovConnor JacobsonEkaterina PostovalovaZhongmin XiangKrystle NomieAleksander BagaevGirish VenkataramanYuanyuan ZhaSravya TumuluruSonali M SmithJustin P Kline

Published in: Journal for immunotherapy of cancer (2023)

These results provide rationale for clinical investigation of TIGIT and PD-1 blockade in lymphomas, including DLBCL.

Keyphrases

diffuse large b cell lymphoma
dna damage
cell cycle
clinical trial
binding protein
oxidative stress